Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 65 for:    depict 2
Previous Study | Return to List | Next Study

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02460978
Recruitment Status : Completed
First Posted : June 3, 2015
Results First Posted : November 6, 2018
Last Update Posted : March 5, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Drug: Dapagliflozin Other: Placebo for dapagliflozin Phase 3

Detailed Description:
Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 815 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
Actual Study Start Date : July 8, 2015
Actual Primary Completion Date : September 2, 2017
Actual Study Completion Date : April 18, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Dapagliflozin 5 mg
Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Tablets

Experimental: Dapagliflozin 10 mg
Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
Drug: Dapagliflozin
Tablets

Placebo Comparator: Placebo
Placebo tablet orally, once daily for 52 weeks
Other: Placebo for dapagliflozin
Tablets




Primary Outcome Measures :
  1. Adjusted Mean Change From Baseline in HbA1c at Week 24 [ Time Frame: Baseline and 24 weeks ]
    To compare the change from baseline in HbA1c between dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment


Secondary Outcome Measures :
  1. Adjusted Mean Percentage Change From Baseline in Total Daily Insulin Dose at Week 24 [ Time Frame: Baseline and 24 weeks ]
    To compare the percent change from baseline in total daily insulin dose with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment

  2. Adjusted Mean Percentage Change From Baseline in Body Weight at Week 24 [ Time Frame: Baseline and 24 weeks ]
    To compare the percentage change from baseline in body weight with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment

  3. Adjusted Mean Change From Baseline in 24-hour Continuous Glucose Monitoring (CGM) Mean Value at Week 24 [ Time Frame: Baseline and 24 weeks ]
    To compare the change from baseline in mean value of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment

  4. Adjusted Mean Change From Baseline in 24-hour CGM Mean Amplitude of Glycemic Excursion (MAGE) Value at Week 24 [ Time Frame: Baseline and 24 weeks ]
    To compare the change from baseline in mean amplitude of glucose excursions (MAGE) of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment

  5. Change From Baseline in the Percent of 24-hour Glucose Readings Obtained From CGM That Falls Within the Target Range of > 70 mg/dL and <= 180 mg/dL (%) at Week 24 [ Time Frame: Baseline and 24 weeks ]
    To compare the change from baseline in the percent of 24-hour glucose readings obtained from CGM that falls within the target range of >70 mg/dL and <=180 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment

  6. Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24 [ Time Frame: Baseline and 24 weeks ]
    To compare dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin for the proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit >=0.5% without severe hypoglycemia events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Type 1 Diabetes mellitus (T1DM)
  • Central laboratory C-peptide < 0.7 ng/ml (0.23 nmol/L)
  • Insulin use for at least 12 months per patient reported or medical records
  • Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening
  • Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening
  • If on MDI insulin administration, subject must be on ≥ 3x injections per day
  • Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%
  • Body mass index (BMI) ≥ 18.5 kg/m2

Exclusion Criteria:

  • History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity
  • Taking any non-insulin antihyperglicemic agent within 1 month prior to screening
  • Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration
  • Taking metformin and/or thiazolidinediones within 2 months prior to screening
  • History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening
  • History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening
  • Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening
  • History of Addison's disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02460978


Locations
Hide Hide 137 study locations
Layout table for location information
United States, California
Research Site
Concord, California, United States, 94520
Research Site
Fresno, California, United States, 93720
Research Site
Los Angeles, California, United States, 90057
Research Site
Orange, California, United States, 92868
Research Site
San Mateo, California, United States, 94401
Research Site
San Ramon, California, United States, 94583
Research Site
Walnut Creek, California, United States, 94598
United States, Colorado
Research Site
Golden, Colorado, United States, 80401
United States, Delaware
Research Site
Newark, Delaware, United States, 19713
United States, Florida
Research Site
Bradenton, Florida, United States, 34201
Research Site
Clearwater, Florida, United States, 33756
Research Site
Fort Lauderdale, Florida, United States, 33312
Research Site
Jacksonville, Florida, United States, 32216
Research Site
Miami Springs, Florida, United States, 33166
Research Site
Miami, Florida, United States, 33156
Research Site
Saint Petersburg, Florida, United States, 33709
Research Site
Tampa, Florida, United States, 33634
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30308
Research Site
Atlanta, Georgia, United States, 30318
Research Site
Roswell, Georgia, United States, 30076
United States, Illinois
Research Site
Chicago, Illinois, United States, 60607
Research Site
Chicago, Illinois, United States, 60611
United States, Iowa
Research Site
Des Moines, Iowa, United States, 50314
United States, Kansas
Research Site
Overland Park, Kansas, United States, 66209
United States, Kentucky
Research Site
Lexington, Kentucky, United States, 40502
Research Site
Lexington, Kentucky, United States, 40503
United States, Michigan
Research Site
Kalamazoo, Michigan, United States, 49008
United States, Minnesota
Research Site
Edina, Minnesota, United States, 55435
United States, Missouri
Research Site
Jefferson City, Missouri, United States, 65109
Research Site
Saint Louis, Missouri, United States, 63110
United States, Nevada
Research Site
Reno, Nevada, United States, 89511
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States, 87109
United States, New York
Research Site
Albany, New York, United States, 12208
Research Site
Flushing, New York, United States, 11355
Research Site
Mineola, New York, United States, 11501
Research Site
New Hyde Park, New York, United States, 11042
Research Site
New York, New York, United States, 10029
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19107-4824
United States, Texas
Research Site
Amarillo, Texas, United States, 79106
Research Site
Austin, Texas, United States, 78731
Research Site
Dallas, Texas, United States, 75231
Research Site
Edinburg, Texas, United States, 78539
Research Site
Mesquite, Texas, United States, 74194
Research Site
San Antonio, Texas, United States, 78229
Research Site
San Antonio, Texas, United States, 78258
United States, Vermont
Research Site
Bennington, Vermont, United States, 05201
United States, Washington
Research Site
Federal Way, Washington, United States, 98003
Argentina
Research Site
Buenos Aires, Argentina, 1180AAX
Research Site
Buenos Aires, Argentina, C1405BCH
Research Site
Caba, Argentina, 1056
Research Site
Cordoba, Argentina, 5000
Research Site
Cordoba, Argentina, X5006IKK
Research Site
Corrientes, Argentina, 3400
Research Site
Mar del Plata, Argentina, B7600FZN
Research Site
Ramos Mejía, Argentina, B1704ETD
Belgium
Research Site
Brussels (Uccle), Belgium, 1180
Research Site
Leuven, Belgium, 3000
Canada, Alberta
Research Site
Calgary, Alberta, Canada, T2V 4J2
Research Site
Edmonton, Alberta, Canada, T6G 2E1
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Research Site
Cambridge, Ontario, Canada, N1R 7L6
Research Site
Hamilton, Ontario, Canada, L8N 3Z5
Research Site
Ottawa, Ontario, Canada, K1H 7W9
Research Site
Smiths Falls, Ontario, Canada, K7A 4W8
Canada, Quebec
Research Site
Sherbrooke, Quebec, Canada, J1H 5N4
Chile
Research Site
Santiago, Chile, 7500010
Research Site
Santiago, Chile, 8053095
Research Site
Temuco, Chile, 4781156
Germany
Research Site
Dresden, Germany, 1307
Research Site
Essen, Germany, 45355
Research Site
Falkensee, Germany, 14612
Research Site
Freiburg im Breisgau, Germany, 79106
Research Site
Hamburg, Germany, 22607
Research Site
Heidelberg, Germany, 69115
Research Site
Oldenburg, Germany, 23758
Research Site
Pohlheim, Germany, 35415
Research Site
Saarlouis, Germany, 66740
Research Site
Sulzbach-Rosenberg, Germany, 92237
Research Site
Wangen, Germany, 88239
Japan
Research Site
Aki-gun, Japan, 735-0021
Research Site
Amagasaki-shi, Japan, 661-0002
Research Site
Chitose-shi, Japan, 066-0032
Research Site
Chuo-ku, Japan, 103-0002
Research Site
Fukuyama-shi, Japan, 721-0927
Research Site
Higashiosaka-shi, Japan, 577-0802
Research Site
Ibusuki-shi, Japan, 891-0401
Research Site
Kagoshima-shi, Japan, 892-0824
Research Site
Kamakura-shi, Japan, 247-0056
Research Site
Kashiwara-shi, Japan, 582-0005
Research Site
Kitakyushu-shi, Japan, 807-0857
Research Site
Koriyama-shi, Japan, 963-8851
Research Site
Kumamoto-shi, Japan, 862-0976
Research Site
Kurume-shi, Japan, 830-8543
Research Site
Miura-shi, Japan, 238-0101
Research Site
Nagoya-shi, Japan, 455-8530
Research Site
Obihiro-shi, Japan, 080-0016
Research Site
Oita-shi, Japan, 870-0855
Research Site
Osaka-shi, Japan, 530-0001
Research Site
Oyama-shi, Japan, 323-0022
Research Site
Sapporo-shi, Japan, 060-0001
Research Site
Shibuya-ku, Japan, 150-0013
Research Site
Shinjuku-ku, Japan, 169-0073
Research Site
Shizuoka-shi, Japan, 424-0855
Research Site
Tsukuba-shi, Japan, 305-0812
Research Site
Ushiku-shi, Japan, 300-1207
Research Site
Uwajima-shi, Japan, 798-8510
Research Site
Yokohama-shi, Japan, 231-8682
Research Site
Yokohama-shi, Japan, 235-0045
Netherlands
Research Site
Hoogeveen, Netherlands, 7909 AA
Research Site
Maastricht, Netherlands, 6020 AZ
Research Site
Utrecht, Netherlands, 3584 CX
Poland
Research Site
Białystok, Poland, 15-351
Research Site
Białystok, Poland, 15-435
Research Site
Gdańsk, Poland, 80-546
Research Site
Krakow, Poland, 31-501
Research Site
Kraków, Poland, 31-156
Research Site
Kraków, Poland, 31-261
Research Site
Lublin, Poland, 20-044
Research Site
Warsaw, Poland, 04736
Research Site
Wroclaw, Poland, 51-685
Russian Federation
Research Site
Novosibirsk, Russian Federation, 630091
Research Site
Saint Petersburg, Russian Federation, 199034
Research Site
Saint-Petersburg, Russian Federation, 194354
Research Site
St. Petersburg, Russian Federation, 191015
Research Site
St.Petersburg, Russian Federation, 194354
Sweden
Research Site
Göteborg, Sweden, 413 45
Research Site
Helsingborg, Sweden, 25220
Research Site
Linkoping, Sweden, 587 58
Research Site
Uddevalla, Sweden, 451 80
Switzerland
Research Site
Olten, Switzerland, 4600
Research Site
St. Gallen, Switzerland, 9016
Research Site
Zollikerberg, Switzerland, 8125
United Kingdom
Research Site
Manchester, United Kingdom, M23 9LT
Research Site
Northampton, United Kingdom, NN1 5BD
Research Site
Oldham, United Kingdom, OL1 2JH
Research Site
Swansea, United Kingdom, SA2 8QA
Research Site
Wakefield, United Kingdom, WF1 4DG
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Anna Maria Langkilde, MD AstraZeneca
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Statistical Analysis Plan  [PDF] September 22, 2017
Study Protocol  [PDF] May 18, 2016

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02460978    
Other Study ID Numbers: MB102-230
2014-004599-49 ( EudraCT Number )
D1695C00007 ( Other Identifier: AstraZeneca )
First Posted: June 3, 2015    Key Record Dates
Results First Posted: November 6, 2018
Last Update Posted: March 5, 2019
Last Verified: February 2019
Keywords provided by AstraZeneca:
Dapagliflozin
Efficacy
Safety
Add on to insulin
Oral Antidiabetic
Type 1 diabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Sodium-Glucose Transporter 2 Inhibitors
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs